<DOC>
	<DOCNO>NCT02455076</DOCNO>
	<brief_summary>The purpose study try achieve similar glycemic control general non-Intensive Care Unit ( non-ICU ) patient Type 2 Diabetes exenatide alone combination basal insulin compare treatment basal bolus insulin alone . The association hyperglycemia poor clinical outcome patient diabetes well establish . Previous study show basal bolus insulin regimen improve glycemic control reduce rate hospital complication compare slide scale regular insulin ( SSRI ) therapy , significant risk hypoglycemia . The investigator compare efficacy safety exenatide alone combination basal insulin control high blood glucose level result low risk hypoglycemia .</brief_summary>
	<brief_title>Exenatide Inpatient Trial : A Randomized Controlled Pilot Trial Safety Efficacy Exenatide ( ByettaÂ® ) Therapy Inpatient Management Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The association hyperglycemia poor clinical outcome patient diabetes well establish . Data previous trial hospitalize patient show strong association hyperglycemia poor clinical outcome , mortality , morbidity , length stay ( LOS ) , infection overall complication . Basal bolus insulin regimen improve glycemic control reduce rate hospital complication compare slide scale regular insulin ( SSRI ) . However , use basal bolus labor intensive , require multiple daily insulin injection , significant risk hypoglycemia . The investigator study treatment exenatide alone combination basal insulin result similar glycemic control lower frequency hypoglycemia treatment basal bolus general non-Intensive Care Unit ( non-ICU ) patient Type 2 Diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . A known history Type 2 Diabetes receive either diet alone oral antidiabetic drug ( OAD ) include insulin secretagogues , pioglitazone , DPP4 inhibitor , metformin monotherapy combination therapy , lowdose insulin &lt; 0.5 unit/kg/day . 2 . Males female age 18 80 year discharge hospital admission general medicine surgery service ( nonIntensive Care Unit set ) . 3 . Subjects admission / randomization BG &lt; 400 mg/dL without laboratory evidence diabetic ketoacidosis ( serum bicarbonate &lt; 18 mEq/L positive serum urinary ketone ) . 4 . Admission HbA1c 7 % 10 % 5 . BMI range : &gt; 25 Kg/m^2 &lt; 45 Kg/m^2 1 . Age &lt; 18 &gt; 80 year 2 . Subjects increase blood glucose ( BG ) concentration , without history diabetes ( stress hyperglycemia ) 3 . Subjects history type 1 diabetes ( suggest BMI &lt; 25 Kg/m^2 require insulin therapy history diabetic ketoacidosis hyperosmolar hyperglycemic state , ketonuria ) . 4 . Treatment highdose ( &gt; 0.5 unit/kg/day ) insulin GLP1 RA past 3 month prior admission . 5 . Patients require ICU care hospital admission . 6 . Recurrent severe hypoglycemia hypoglycemic unawareness . 7 . Subjects gastrointestinal obstruction , gastroparesis , history pancreatitis expect require gastrointestinal suction . 8 . Patients clinically relevant pancreatic gallbladder disease . 9 . Patients unstable rapidly progress renal disease severe renal impairment ( creatinine clearance &lt; 30 ml/min ) 10 . Patients clinically significant hepatic disease ( cirrhosis , jaundice , endstage liver disease ) , 11 . History hypersensitivity exenatide 12 . Treatment oral injectable corticosteroid ( equal prednisone dose &gt; 5 mg/day ) , parenteral nutrition immunosuppressive treatment . 13 . Patients history heavy alcohol use ( female &gt; 2 drink per day , male &gt; 3 drink per day ) drug abuse within 3 month prior admission . 14 . Mental condition render subject unable understand nature , scope , possible consequence study . 15 . Female subject pregnant breast feeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypoglycemia</keyword>
</DOC>